The m6A writer METTL5 promotes LUSC progression by enhancing CDC45 translation.

The m6A writer METTL5 promotes LUSC progression by enhancing CDC45 translation. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article The m6A writer METTL5 promotes LUSC progression by enhancing CDC45 translation. Jianjun Fu, Yang Yan This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4891277/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Abnormal N6-methyladenosine (m6A) modifications were associated with the occurrence, development, and metastasis of Lung squamous cell carcinoma (LUSC). However, the functions and mechanisms of m6A regulators in LUSC remained largely unclear. Here, we identified that METTL5 was specifically overexpressed and associated with poor prognosis in LUSC. Importantly, METTL5 promoted LUSC cell progression in an m6A-dependent manner, METTL5 silencing significantly inhibited proliferation and migratory ability of tumor cells in vitro. Mechanistically, METTL5 increased the translation of cell division cycle protein 45 (CDC45) via 18S rRNA methyltransferase. Therefore, our findings indicated that m6A writer METTL5 contributed to tumorigenesis and poor prognosis, providing a potential prognostic biomarker and therapeutic target for LUSC. Biological sciences/Cancer/Tumour biomarkers Biological sciences/Cancer/Lung cancer/Non small cell lung cancer LUSC METTL5 CDC45 m6A modification Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction Lung cancer remains one of the most frequently diagnosed and the deadliest cancer types worldwide[ 1 ]. Non-small cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two most frequent lung cancers. NSCLC is classified into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and large cell carcinomas[ 2 ]. Unfortunately, most patients with LUSCs are diagnosed at an advanced stage with high mortality[ 3 ]. Although treatments have improved significantly recently, the efficacy is still far from ideal. Therefore, it is imperative to further illustrate the molecular pathogenesis of LUSC to develop novel therapeutic strategies. Emerging evidence has demonstrated that dysregulated m6A-associated proteins and m6A modifications play a crucial role in the initiation and progression of cancer[ 4 ]. N6-methyladenosine (m6A) modifications are dynamic and reversible posttranscriptional RNA modifications in messengerRNA (mRNA), transferRNA (tRNA), and ribosomalRNA (rRNA) that are mediated by m6A regulators, such as methyltransferases (“writers”: METTL3, METTL5, METTL14, and WTAP), demethylases (“erasers”: ALKBH5 and FTO), and m6A-binding proteins (“readers”: YTHDs and IGF2BPs), which regulates RNA splicing and influences the stability and translation of modified RNAs[ 5 ]. Interestingly, Methyltransferase 5, N6-adenosine (METTL5) is an 18S rRNA methyltransferase that increases protein translation activity in cancer and is essential for tumorigenesis[ 6 ]. Although the aberrant expression of METTL5 has been demonstrated to play critical roles in regulating biological processes[ 7 , 8 ], the role of METTL5 m6A writer protein in the progression of LUSC remain poorly understood. Therefore, it is necessary to elucidate the biological importance of m6A regulators in promoting tumors. Cell division cycle protein 45 (CDC45) is the core component of CMG (CDC45-MCMs‐GINS) complex that plays a critical role in forming the fully active form of DNA helicase[ 9 ]. CDC45 knockdown has been demonstrated to inhibit cell proliferation and leads to cell death due to the inhibition of DNA replication and G1‐phase arrest[ 10 ]. Here, we demonstrated that a critical m6A writer, METTL5 facilitating CDC45 translation via 18S rRNA methyltransferase to promote LUSC carcinoma progression. In summary, our results revealed that m6A modulation on cancer cell plasticity and provided potential therapeutic targets for LUSC. Materials and Methods Data collection RNA-sequence (RNA-seq) transcriptional data and clinical information of LUSC were downloaded from the Cancer Genome Atlas (TCGA) database ( https://cancergenome.nih.gov/ ). Construction of a protein-protein interaction (PPI) network The mRNAs were included in a PPI network using the STRING database ( https://string-db.org/ ) with a confidence score of > 0.8. Cytoscape (version 3.8.1) was used to visualise the PPI network[ 11 ]. survival analysis Kaplan-Meier survival analysis was used to evaluate the difference in overall survival (OS) between the two groups using the log-rank test. Evaluation of predictive ability Univariate Cox regression analysis and multivariate Cox regression analysis was performed to evaluate the resolution ability of METTL5. The predictive performance of METTL5 within 0.5, 1, and 1.5 years was assessed by receiver operating characteristic (ROC) curves using the survivalROC package. Gene set variation analysis (GSVA) The variation in biological processes between low- and high-METTL5 groups were performed by GSVA analysis using the R package 'GSVA'. Differentially expressed genes (DEGs) analysis The “limma” package of R software was used to identify the DEGs between high- and low- METTL5 expression groups. The cutoff criteria were set as | log2 fold change (FC) | > 0.5 and p < 0.05. DEGs between normal and glioma tissues were selected based on the Wilcoxon rank test. Cell culture and cell culture Human LUSC cells lines (H1975 and A594 cells) were purchased from the Chinese Academy of Sciences Cell Bank and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) containing 10% FBS (HyClone) and 1% penicillin–streptomycin (P/S). Colony Formation Assay For the colony formation assay, cells were seeded in 6-well plates at a density of 1 × 10 3 cells per well and cultured for the 7–10 days. The colonies were then stained with 0.2% crystal violet and documented. CCK-8 assay. CCK8 assay was used to assess tumor cells viability following the manufacturer’s instructions. GBM cells (2 × 10 3 cells, 100 µL per well) were seeded into 96-well plates, and CCK-8 reagent was added at 24, 48, 72, and 96 hours. The absorbance at 450 nm was measured using a microplate reader. Transwell migratory experiment To evaluate cell migratory ability, tumor cells (5 × 10 4 cells) were seeded into the upper chamber of Transwell inserts. The lower chamber was filled with 500 µL of complete medium containing 10% FBS to induce cell migration. After 24 hours of incubation, cells that migrated through the membrane were stained with 0.2% crystal violet and photographed by microscopy. Wound healing assay Cells were seeded in 6-well plate and incubated overnight. Next day, the inserts were removed, and serum-free medium was added. After 36 h. ImageJ was used to calculate the migratory rate. Western blot RIPA buffer (Beyotime, Shanghai) was used to extract total protein from cells, then the protein concentration was detected by the BCA kit (Beyotime, China). Protein concentrations were determined using the BCA kit (Beyotime, China). Lysates were then separated by SDS-PAGE gels and transferred onto polyvinylidene difluoride (PVDF) membranes. Membranes were incubated overnight at 4°C with specific primary antibodies. After washing, membranes were incubated with HRP-conjugated secondary antibodies at room temperature for 2 hours. Chemical Reagents, Antibodies, and Transfection Anti-METTL5 (proteintech, China, Cat# 16791-1-AP); CDC45 (proteintech, China, Cat# 15678-1-AP; METTL5 and CDC45 overexpression plasmids and short hairpin RNA (shRNA) METTL5 ( Table S4 ) were purchased from GeneChem (Shanghai, China). All transfections were performed according to the manufacturers’ instructions (38589907). Quantitative RT–PCR Total RNA was extracted from cells using TRIzol reagent (Invitrogen, USA) according to the manufacturer’s instructions. 1 µg of RNA was applied for reverse transcription (Cat. #R323-01, Vazyme). Real-time PCR analysis was performed using SYBR Premix Ex TaqTM (Tli RNaseH Plus) (TaKaRa, Dalian, China). The amplification primers were listed in Table S5 . Polysome profiling Briefly, cells were incubated with Cycloheximide (CHX; Sigma–Aldrich) for 5 min at 37°C, and then the cells were washed with PBS containing 100 µg/mL CHX after removing the medium. Next, 400 µL of Triton X-100‐containing lysis buffer were added and incubated with the cells for 15 min. Each cell suspension was centrifuged, and the supernatant was collected. Subsequently, a 10%‐50% sucrose gradient was prepared in lysis buffer without Triton X‐100. Cell lysates were loaded onto a sucrose gradient and centrifuged at 30000 rpm for 4h at 4°C. The samples were then fractionated and analyzed with a Gradient Station. Analysis of modified nucleosides by Liquid chromatography-Mass spectrometry (LC/MS) The 18S rRNAs and mRNA were purified from cells by 10–50% sucrose velocity centrifugation. Briefly, 1 × 107 cells were seeded and detached in PBS at 0°C and resuspended in 500 µl Buffer. The cell suspension was centrifuged at 20 000 × g for 20 min at 4°C, and extracts were thawed on ice and loaded on a 10–50% sucrose density gradient and centrifuged at 23 000 × g for 20 h in a Beckman L-90K centrifuge with a SW41Ti rotor. RNA was extracted from peak fractions with TRIreagent (Sigma #T9424). LC/MS was used to analyze the m6A levels of 18S rRNAs and mRNA[ 8 ]. Dual-luciferase reporter assays Luciferase reporter expression was measured using the Dual Luciferase Assay Kit (Promega, Madison, WI, USA). The results were normalized for transfection efficiency using Renilla luciferase activity. Statistical Analysis Statistical analyses were performed using R, version 4.2.3. Survival analysis was performed by the Kaplan–Meier method with a log rank test. Correlations were analyzed by using Pearson's correlation. Univariate and multivariable survival analysis were performed using Cox regression analysis. A two-tailed Student's t‐test was used to compare between groups for statistical significance. All experiments were performed for at least 3 times independently under similar conditions, unless otherwise specified in the figure captions. In all cases, p value < 0.05 was considered statistically significant. Results High-throughput library screening identifies METTL5 as a core m6A regulator in LUSC. Based on TCGA data, a total of 28 m6A regulators including 10 writers, 3 erasers and 15 readers were screened for subsequent studies. The process of m6A methylation was dynamically and reversibly regulated by these m6A regulators (Fig. 1 a and Table S1 ). The investigation of CNV alteration frequency showed a prevalent CNV alteration in 28 regulators and most were focused on the amplification in copy number. YTHDF1, VIRMA, and METTL5 showed amplification frequencies, whereas ZC3H13 and RBM15 had CNV copy number deletions (Fig. 1 b). In addition, the locations of CNV alterations in the 28 m6A regulators on the chromosomes are shown in Fig. 1 e. Compared to normal tissues, m6A regulators with amplificated CNV demonstrated remarkedly higher expression in LUSC tissues, and vice versa (Fig. 1 b and c ). The comprehensive landscape of m6A regulator interactions, regulator connection and their prognostic significance for LUSC patients was depicted with the m6A regulator network ( Fig. 1 d ) . We found that not only exhibited significant correlations in expression within the same functional category but also among writers, erasers, and readers. Importantly, based on risk and survival analysis, the 3 best hints, METTL5, HNRNPC, and IGF2BP3, were screen, of which METTL5 overexpression exhibited the worst overall survival (Fig. 1 f-h). Taken together, these data further shed light on the oncogenic role of METTL5 in tumour progression. METTL5 is an independent prognostic factor in LUSC . Based on the TCGA dataset, high METTL5 expression was related with higher risk score and poorer OS status in LIHC patients (Fig. 2 a). Moreover, the receiver operating characteristics (ROC) curve analysis of the promising predictive value for METTL5 expression showed that the areas under the curves (AUCs) for 0.5-, 1-, and 1.5-year OS were 0.613, 0.611, and 0.620, respectively (Fig. 2 b). The multi-index ROC analysis revealed that the AUC of METTL5 was significantly better than those of other clinicopathological indicators (Fig. 2 b) (such as age, gender, and stage). In univariate Cox analysis, stage (p < 0.009) and risk score (p < 0.017) were significantly correlated with OS (Fig. 2 c). In multivariate Cox analysis, only METTL5 (p < 0.017) was an independent prognostic factor (Fig. 2 d). Together, these data illustrate METTL5 is an independent prognostic factor in LUSC. METTL5 promotes tumor progression in LUSC . To explore the biological function of METTL5 in LUSC, we transfected NETTL5 knockdown or overexpression in H1975 and A549 cells. Transfection efficiency was evaluated by western blot and qPCR (Fig. 3 a-d). Colony formation assays and CCK-8 showed that METTL5 regulated cell proliferation and colony formation ability (Fig. 3 e-f). In addition, METTL5 also impacted cell migratory ability in H1975 and A549 cells (Fig. 3 g-h). Therefore, these results suggested that METTL5 promotes tumor progression in LUSC. Functional annotations of METTL5 in LUSC . The correlations between METTL5 expression and clinical properties were examined in the TCGA dataset. High METTL5 expression level was related with older age, gender, and tumor stage (Fig. 4 a). Single-sample GSEA (ssGSEA) algorithm was used to evaluate the associations between METTL5 expression and immune cell infiltration, the results showed that high-METTL5 patients were slightly increased immune activity than the low-METTL5 patients (Fig. 4 b). Additionally, Gene set variation analysis (GSVA) was performed to explore the underlying molecular mechanisms differing in the high-METTL5 and low-METTL5 subgroups of LIHC patients. The results showed that high- METTL5 patients were mainly related with mitotic spindle, G2M checkpoint, E2F targets (Fig. 4 c ) , and cell cycle signaling pathway in the TCGA dataset (Fig. 4 d). Protein–protein interaction network and univariate cox regression analyses To further investigate the potential biological behavior of METTL5 modification pattern, we determined the DEGs between high- METTL5 and low- METTL5 expression groups using limma package. The PPI network of the interactions among DEGs was performed using STRING database (confidence value > 0.8) (Fig. 5 a), which were visualized in Cytoscape v3.8.2 (Fig. 5 b). The top 30 genes were represented based on the number of nodes using bar plots, which may serve as hub nodes in the network (Fig. 5 c and Table S2 ). In addition, univariate Cox regression analyses showed that 31 genes were of prognostic significance among the DEGs (Fig. 5 d and Table S3 ). METTL5 promoted cell division cycle protein 45 (CDC45) translation via 18S rRNA methyltransferase. Based on differentially expressed genes (DEGs) between high-METTL5 and low-METTL5 expression groups, CDC45 was identified through the intersection analysis of the top 10 prognostic significance and the top 10 hub genes in the PPI network (Fig. 6 a). Subsequently, the expression and potential role of CDC45 were further explored using the TCGA dataset. The expression of CDC45 was significantly increased in LUSC comparing normal tissue (Fig. 6 b-c). K-M analysis showed that LUSC patients with CDC45 overexpression had poor survival (Fig. 6 d). Interestingly, METTL5 knockdown or overexpression regulated CDC45 protein expression but did not significantly alter the translation levels of CDC45 (Fig. 6 e-f). METTL5 regulates ribosome function by methylating 18S rRNA, resulting in changing indicated proteins levels[ 7 ]. Then, polysome fractionation analysis was used to determine whether METTL5 has an impact on CDC45 translation in METTL5-WT and METTL5‐KD cells, the results showed that METTL5 knockdown had no effect on the profile of GAPDH mRNA, whereas CDC45 mRNA was transferred from the heavier polysomal fractions to the lighter fractions (Fig. 6 g-h), which revealed that METTL5 regulated CDC45 mRNA translation. Therefore, we investigated whether CDC45 translational activity is dependent on METTL5 methylase activity. Importantly, LC/MS showed that METTL5 knockdown reduced the m6A level of 18S rRNA but had no effect on the m6A level of mRNA after separation of rRNA and mRNA (Fig. 6 i-j), which suggested that the translation of CDC45 is directly dependent on METTL5 18S rRNA methyltransferase activities. In addition, METTL3‐METTL14 complex, as a well‐known mRNA m6A methyltransferase, has been demonstrated to mediates DNA m6A methylation (m6dA) in vitro[ 12 ]. Notably, we were unable to fund modification changes in the m6da region of genomic DNA following METTL5 knockdown (Fig. 6 k), which demonstrated that METTL5 is not involved in DNA methylation. Subsequently, the luciferase reporter assay determined that METTL5 had no effect on CDC45 promoter activity (Fig. 6 i). Taken together, these dates reveal that METTL5 was a pure RNA methylase and exhibited no regulatory effect on DNA methylation. METTL5 promotes LUSC progression through CDC45 expression . Due to silencing METTL5 could reduce CDC45 expression, rescue experiments were carried out to verify the interaction between METTL5 and CDC45 in LUSC progression. As expected, CDC45 overexpression could partially counteract the antitumor effects of MEETL5 knockdown on cell viability (Fig. 7 a), colony formation (Fig. 7 b) and migration (Fig. 7 c-d). In addition, overexpression of CDC45 also promoted cell proliferation, colony formation and migration in H1975 and A549 cells, confirming the oncogenic effects of CDC45 (Fig. 7 a-d). Collectively, METTL5 promotes LUSC progression through CDC45 expression. Discussion N6-methyladenosine (m6A) modification, as crucial regulators of LUSC progression, highlight the importance of understanding the crosstalk between these biological processes[ 13 ]. Accumulating evidence has indicated that METTL5 is highly expressed and promotes tumor progression[ 6 , 7 , 14 , 15 ], however, the role of METTL5 in LUSC is not explored. In this study, among 28 m6A regulators (writers:10, erasers:3 and readers:15), we firstly identified the key m6A regulator METTL5 in LUSC using TCGA dataset through CNV alteration frequency, differential analysis, correlation analysis, and survival analysis. Then, we demonstrated that METTL5 was an independent prognostic factor in LUSC based on ROC curve, univariate analysis, and multivariate analysis. METTL5 has been confirmed to be overexpressed in a variety of tumors and affects patient prognosis, such as hepatocellular carcinoma[ 8 , 16 ], Intrahepatic cholangiocarcinoma (ICC)[ 14 ], and breast cancer [ 7 ]. We confirmed bioinformatically that the METTL5 expression was significantly higher in LUSC than in normal samples, and patients with high METTL5 expression had a worse prognosis. In vitro experiments, we demonstrated that METTL5 promotes tumor progression in LUSC via CCK-8, colony formation assay, transwell migration assay, and wound healing assay. Next, we further explored the function of METTL5 in LUSC, the results showed older age, gender, and tumor stage were positive with METTL5 expression level. Surprisingly, high- METTL5 expression were no obvious immune activity compared to low-METTL5 patients. METTL5, as one of the 18S rRNA methyltransferases, is important in protein translation and polysome formation[ 6 ]. Interestingly, METTL5 is an rRNA m6A methyltransferase and is not responsible for the m6A modification of mRNA[ 8 ]. Importantly, METTL5 enhances protein translation in cancer, reduces apoptosis, and promotes cell cycle progression[ 7 ]. Similarly, our GSVA showed high-METTL5 patients were mainly related with G2M checkpoint, E2F targets, and cell cycle signaling pathway. To further investigate the modification pattern of METTL5, DEGs were screened between high-METTL5 and low-METTL5 expression groups, and then subjected to the PPI network analysis and univariate Cox regression analyses. Finally, screening CDC45 may be regulated by METTL5 based on the intersection analysis of the top 10 prognostic significance and hub genes in the PPI network. CDC45 is an irreplaceable factor to initiate DNA replication in eukaryotic cells. Dysfunction of CDC45 results in cell proliferation inhibition even cell death[ 17 , 18 ]. We confirmed bioinformatically that CDC45 was significantly upregulated in LUSC comparing normal tissue, and CDC45 overexpression showed poor survival. Notably, our results demonstrated that translation of CDC45 is directly dependent on METTL5 18S rRNA methyltransferase activities. In vitro experiments, rescue experiments were carried out to verify METTL5 promotes LUSC progression through enhancing CDC45 translation. Above data suggested METTL5-CDC45 axis has an important role in LUSC progression and provides a novel potential prognostic biomarker for LUSC. Conclusion In summary, we demonstrated that the m6A writer METTL5 contributes to the tumorigenesis and poor prognosis of LUSC by enhancing CDC45 translation, providing a distinct mechanistic insight in m6A-dependent, which should be helpful for developing CDC45 signaling‐targeted inhibitors. Declarations Availability of data and materials Clinical information and high-throughput sequencing-counts were retrieved from the TCGA data (https://www.cancer.gov/ccg/research/genome-sequencing/tcga) portal, which is a publicly available database. Acknowledgements The reviewers are grateful for their helpful comments on this article. Consent for publication Not applicable Authors' contributions All authors contributed to the analysis of data in this study. Conception and design: JF; Acquisition, analysis, and interpretation of data: JF and YY; Writing, review, and/or revision of the manuscript: YY; Performing the laboratory experiments: JF and YY; Administrative, technical, or material support: JF; Study supervision: JF. All authors contributed to the article and approved the submitted version. Funding This work was supported by the Science and Technology Plan of Jiangxi Provincial Health Commission, China (SKJP220212042). Competing interests The authors declare that there are no potential conflicts of interest. References Yang, X. et al. m(6) A-Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis. Adv. Sci. (Weinh) . 10 (20), e2206744 (2023). Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72 (1), 7–33 (2022). Lau, S. C. M., Pan, Y., Velcheti, V. & Wong, K. K. Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer Cell. 40 (11), 1279–1293 (2022). Wang, Y. et al. Epigenetic modification of m(6)A regulator proteins in cancer. Mol. Cancer . 22 (1), 102 (2023). Deng, L. J. et al. m6A modification: recent advances, anticancer targeted drug discovery and beyond. Mol. Cancer . 21 (1), 52 (2022). van Tran, N. et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res. 47 (15), 7719–7733 (2019). Rong, B. et al. Ribosome 18S m(6)A Methyltransferase METTL5 Promotes Translation Initiation and Breast Cancer Cell Growth. Cell. Rep. 33 (12), 108544 (2020). Xia, P. et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun. (Lond) . 43 (3), 338–364 (2023). Fu, Y., Lv, Z., Kong, D., Fan, Y. & Dong, B. High abundance of CDC45 inhibits cell proliferation through elevation of HSPA6. Cell. Prolif. 55 (7), e13257 (2022). Simon, A. C., Sannino, V., Costanzo, V. & Pellegrini, L. Structure of human Cdc45 and implications for CMG helicase function. Nat. Commun. 7 , 11638 (2016). Yu, W. et al. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma. Front. Immunol. 12 , 706936 (2021). Woodcock, C. B. et al. Human MettL3-MettL14 complex is a sequence-specific DNA adenine methyltransferase active on single-strand and unpaired DNA in vitro. Cell. Discov . 5 , 63 (2019). Li, N. & Zhan, X. Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 11 (3), 485–504 (2020). Dai, Z. et al. METTL5-mediated 18S rRNA m(6)A modification promotes oncogenic mRNA translation and intrahepatic cholangiocarcinoma progression. Mol. Ther. 31 (11), 3225–3242 (2023). Leismann, J. et al. The 18S ribosomal RNA m(6) A methyltransferase Mettl5 is required for normal walking behavior in Drosophila. EMBO Rep. 21 (7), e49443 (2020). Peng, H. et al. N(6)-methyladenosine (m(6)A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. Nat. Metab. 4 (8), 1041–1054 (2022). Yadav, A. et al. DNA replication protein Cdc45 directly interacts with PCNA via its PIP box in Leishmania donovani and the Cdc45 PIP box is essential for cell survival. PLoS Pathog . 16 (5), e1008190 (2020). Dang, H. Q. & Li, Z. The Cdc45.Mcm2-7.GINS protein complex in trypanosomes regulates DNA replication and interacts with two Orc1-like proteins in the origin recognition complex. J. Biol. Chem. 286 (37), 32424–32435 (2011). Additional Declarations No competing interests reported. Supplementary Files SppulementaryTableS15.xlsx FigureS1.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4891277","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":354208764,"identity":"c241e119-adc1-4521-a456-26965747d20d","order_by":0,"name":"Jianjun Fu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAvElEQVRIie3RoQ7CMBCA4S5LVtOhm0DYK3SpXQKPcpjOgCCYypGQzvAAYHgMguxS2zfA9BGQkzQILIcjob++T9wdIanUD0Y7AnLUfF7Q3uIIs5EQ38gJ84AmJM8OanXhS4EkHMJu27nWcAJk1FcUAXm+uY2Z7m129PfPZBGJKH0kMwt5ZhCEvYhxbcFB4IksjYIvCAtQn3xTm3jkAbULo2slHppXVd8PYdQIEpF6/8Ni5mPUBeRkKpVK/WtPFNE8vWmCW2kAAAAASUVORK5CYII=","orcid":"","institution":"Gaoxin Branch of The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","correspondingAuthor":true,"prefix":"","firstName":"Jianjun","middleName":"","lastName":"Fu","suffix":""},{"id":354208765,"identity":"6007ec1a-7c9b-44ba-970b-2be7412b9633","order_by":1,"name":"Yang Yan","email":"","orcid":"","institution":"Gaoxin Branch of The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","correspondingAuthor":false,"prefix":"","firstName":"Yang","middleName":"","lastName":"Yan","suffix":""}],"badges":[],"createdAt":"2024-08-10 10:23:04","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4891277/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4891277/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":64929616,"identity":"d7932a20-83ac-450a-8d9e-349bd9d622d2","added_by":"auto","created_at":"2024-09-20 13:44:07","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1083301,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHigh-throughput library screening identifies the key m6A regulator in LUSC\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003ea. Essential regulators in m6A RNA methylation events, and their biological functions.\u003c/p\u003e\n\u003cp\u003eb. The CNV variation frequency of m6A regulators in TCGA cohort. The height of the column represented the alteration frequency. The deletion frequency, blue dot; The amplification frequency, red dot.\u003c/p\u003e\n\u003cp\u003ec. Differential expression of m6a regulators between normal and LUSC tissues. LIHC, red; Normal, blue. Significant results are indicated as ***p \u0026lt; 0.001, **p \u0026lt; 0.01, and *p \u0026lt; 0.05.\u003c/p\u003e\n\u003cp\u003ed. The interaction of expression on 28 m6A regulators in LUSC. Different biological functions of m6A regulators were depicted by circles in different colors. The lines linking regulators showed their interactions, pink represented positive correlation, and blue represented negative correlation. The circle size represented the effect of each regulator on the prognosis by P-value. Purple dots in the circle showed risk factors of prognosis; Green dots in the circle showed favorable factors of prognosis.\u003c/p\u003e\n\u003cp\u003ee. The location of CNV alteration of 28 m6A regulators on chromosomes in TCGA-GBM cohort.\u003c/p\u003e\n\u003cp\u003ef-g. Kaplan–Meier survival analysis showed that indicated genes exhibited prognosis in LUSC patients based on TCGA data.\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/720ed987d2a583dcf6be4f19.jpg"},{"id":64929186,"identity":"4091c493-28df-42d4-9a62-bcf930e3ac57","added_by":"auto","created_at":"2024-09-20 13:36:07","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":467987,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMETTL5 is an independent prognostic factor in LUSC\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003ea. Distribution of risk score, OS, and OS status in the high and low METTL5 subgroups.\u003c/p\u003e\n\u003cp\u003eb. The AUC value and cutoff point obtained in the TCGA set, ROC curve analysis within 0.5, 1, and 1.5 years, and multivariate ROC curve analysis showing that the superior prognostic performance of the METTL5 expression compared to other clinical indicators.\u003c/p\u003e\n\u003cp\u003ec. Univariate analysis of the METTL5 expression and other clinical information in TCGA GBM cohort.\u003c/p\u003e\n\u003cp\u003ed. Multivariate analysis of the METTL5 expression and other clinical information in TCGA GBM cohort.\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/6c047266b9c728109d8fb33a.jpg"},{"id":64929180,"identity":"918d98c6-676e-4c4e-99ad-08c8bfc010a1","added_by":"auto","created_at":"2024-09-20 13:36:06","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":828434,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMETTL5 promotes tumor progression in LUSC\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003ea-d.\u003cstrong\u003e \u003c/strong\u003eTransfection knockdown or overexpression efficiencies was validated by western blot and qPCR, respectively.\u003c/p\u003e\n\u003cp\u003ee-f. colony formation assay and CCK-8 was used to analyze the proliferation viability of METTL5 in LUSC cell. All the data are presented as the mean ± standard deviation (n = 3). *P \u0026lt; 0.05, **P \u0026lt; 0.01, compared with the control group.\u003c/p\u003e\n\u003cp\u003eg-i. Transwell migration assay and wound healing assay was used to analyze the migration viability of METTL5 in LUSC cell. All the data are presented as the mean ± standard deviation (n = 3). *P \u0026lt; 0.05, **P \u0026lt; 0.01, compared with the control group.\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/c2426c8493b266eb4a0da0b4.jpg"},{"id":64929188,"identity":"b84b9b7b-d6ba-44e5-8a55-f659caa2a41c","added_by":"auto","created_at":"2024-09-20 13:36:07","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1301929,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eFunctional annotations of METTL5 in LUSC.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ea. Associations between METTL5 expression and clinical features of LUSC.\u003c/p\u003e\n\u003cp\u003eb. Correlations between METTL5 expression and immune-interrelated signatures, as determined by ESTIMATE, immune, stromal, and tumor purity scores.\u003c/p\u003e\n\u003cp\u003ec. GSVA analyses (HALLMARK) of METTL5 in LIHC patients.\u003c/p\u003e\n\u003cp\u003ed. GSVA analyses (KEGG) of METTL5 in LIHC patients.\u003c/p\u003e","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/90dc541e09b54d3920e96b02.jpg"},{"id":64929184,"identity":"3be58d58-a6e7-485e-8ad3-e125b48d396d","added_by":"auto","created_at":"2024-09-20 13:36:07","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":791138,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eProtein–protein interaction network and univariate cox regression analyses\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ea. The PPI network based on the STRING confidence score \u0026gt; 0.8.\u003c/p\u003e\n\u003cp\u003eb. The visualization of the PPI network.\u003c/p\u003e\n\u003cp\u003ec. The top 30 genes ordered by the number of nodes.\u003c/p\u003e\n\u003cp\u003ed. Univariate Cox analyses of DEGs\u003c/p\u003e","description":"","filename":"Figure5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/18452251668974bb58c4dec6.jpg"},{"id":64929189,"identity":"57d3cfb7-9072-4422-8038-84976112164d","added_by":"auto","created_at":"2024-09-20 13:36:08","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":676840,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMETTL5 promoted cell division cycle protein 45 (CDC45) translation via 18S rRNA methyltransferase.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ea. The Venn plot showed CDC45 was identified based on the intersection analysis.\u003c/p\u003e\n\u003cp\u003eb-c. The expression of CDC45 between normal and tumor tissues.\u003c/p\u003e\n\u003cp\u003ed. The survival analysis of LUSC patients with low and high CDC45 expression.\u003c/p\u003e\n\u003cp\u003ee-f. Relative CDC45 mRNA and protein expression levels in LUSC cells transected with METTL5 knockdown or overexpression.\u003c/p\u003e\n\u003cp\u003eg-h. The polysomes of METTL5‐WT and METTL5‐KD cells were extracted and subjected to a 10% to 50% sucrose gradient ultracentrifugation. The mRNA expression level in each fraction was determined by qRT‐PCR (upper) and visualized by DNA agarose gel (lower).\u003c/p\u003e\n\u003cp\u003ei-j. LC/MS was performed with an m6A antibody.\u003c/p\u003e\n\u003cp\u003ek. m6A DNA methylation assay detected alterations in m6dA of genomic DNA in METTL5-WT and METTL5-KD cells.\u003c/p\u003e\n\u003cp\u003el. Dual luciferase reporter assay results indicated that METTL5 exhibits no regulatory effect on DNA methylation. n = 3 independent experiments, ns means no significant difference.\u003c/p\u003e","description":"","filename":"Figure6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/22980ac4a89e1795cfa3072d.jpg"},{"id":64929618,"identity":"82a82ed7-f888-4042-aa1f-5d659327a971","added_by":"auto","created_at":"2024-09-20 13:44:07","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":725540,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMETTL5 promotes LUSC progression through CDC45 expression\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003ea. Cell viability was measured in METTL5 silencing cells with or without overexpression of CDC45.\u003c/p\u003e\n\u003cp\u003eb. Colony formation assay indicated the rescue effect of CDC45 on METTL5 silencing.\u003c/p\u003e\n\u003cp\u003ec-d. Transwell migration assays and wound healing assays were performed in METTL5-deficient cells with or without overexpression of CDC45. All the data are presented as the mean ± standard deviation (n=3). **P\u0026lt;0.01, compared with the control group.\u003c/p\u003e","description":"","filename":"Figure7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/d636a58085db3bea5f76a44b.jpg"},{"id":65065387,"identity":"bac57c2c-4e86-47bf-bc57-ef324f1a1499","added_by":"auto","created_at":"2024-09-23 08:47:32","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":6592662,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/1ec5cdc2-7de5-4cf6-9672-ce7f388fdd6b.pdf"},{"id":64929183,"identity":"0157f9aa-8fd7-4a15-939d-79ede7361e25","added_by":"auto","created_at":"2024-09-20 13:36:07","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":40777,"visible":true,"origin":"","legend":"","description":"","filename":"SppulementaryTableS15.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/d5947109dd8a0110c1484515.xlsx"},{"id":64929185,"identity":"ffb9e174-6e11-495b-a6f5-fc75d9bc9b75","added_by":"auto","created_at":"2024-09-20 13:36:07","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":257021,"visible":true,"origin":"","legend":"","description":"","filename":"FigureS1.docx","url":"https://assets-eu.researchsquare.com/files/rs-4891277/v1/2edf5f6c94578de53131ab0e.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"The m6A writer METTL5 promotes LUSC progression by enhancing CDC45 translation.","fulltext":[{"header":"Introduction","content":"\u003cp\u003eLung cancer remains one of the most frequently diagnosed and the deadliest cancer types worldwide[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Non-small cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two most frequent lung cancers. NSCLC is classified into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and large cell carcinomas[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Unfortunately, most patients with LUSCs are diagnosed at an advanced stage with high mortality[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Although treatments have improved significantly recently, the efficacy is still far from ideal. Therefore, it is imperative to further illustrate the molecular pathogenesis of LUSC to develop novel therapeutic strategies.\u003c/p\u003e \u003cp\u003eEmerging evidence has demonstrated that dysregulated m6A-associated proteins and m6A modifications play a crucial role in the initiation and progression of cancer[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. N6-methyladenosine (m6A) modifications are dynamic and reversible posttranscriptional RNA modifications in messengerRNA (mRNA), transferRNA (tRNA), and ribosomalRNA (rRNA) that are mediated by m6A regulators, such as methyltransferases (\u0026ldquo;writers\u0026rdquo;: METTL3, METTL5, METTL14, and WTAP), demethylases (\u0026ldquo;erasers\u0026rdquo;: ALKBH5 and FTO), and m6A-binding proteins (\u0026ldquo;readers\u0026rdquo;: YTHDs and IGF2BPs), which regulates RNA splicing and influences the stability and translation of modified RNAs[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Interestingly, Methyltransferase 5, N6-adenosine (METTL5) is an 18S rRNA methyltransferase that increases protein translation activity in cancer and is essential for tumorigenesis[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Although the aberrant expression of METTL5 has been demonstrated to play critical roles in regulating biological processes[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e], the role of METTL5 m6A writer protein in the progression of LUSC remain poorly understood. Therefore, it is necessary to elucidate the biological importance of m6A regulators in promoting tumors.\u003c/p\u003e \u003cp\u003eCell division cycle protein 45 (CDC45) is the core component of CMG (CDC45-MCMs‐GINS) complex that plays a critical role in forming the fully active form of DNA helicase[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. CDC45 knockdown has been demonstrated to inhibit cell proliferation and leads to cell death due to the inhibition of DNA replication and G1‐phase arrest[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eHere, we demonstrated that a critical m6A writer, METTL5 facilitating CDC45 translation via 18S rRNA methyltransferase to promote LUSC carcinoma progression. In summary, our results revealed that m6A modulation on cancer cell plasticity and provided potential therapeutic targets for LUSC.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eData collection\u003c/h2\u003e \u003cp\u003eRNA-sequence (RNA-seq) transcriptional data and clinical information of LUSC were downloaded from the Cancer Genome Atlas (TCGA) database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://cancergenome.nih.gov/\u003c/span\u003e\u003cspan address=\"https://cancergenome.nih.gov/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eConstruction of a protein-protein interaction (PPI) network\u003c/h2\u003e \u003cp\u003eThe mRNAs were included in a PPI network using the STRING database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://string-db.org/\u003c/span\u003e\u003cspan address=\"https://string-db.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) with a confidence score of \u0026gt;\u0026thinsp;0.8. Cytoscape (version 3.8.1) was used to visualise the PPI network[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003esurvival analysis\u003c/h2\u003e \u003cp\u003eKaplan-Meier survival analysis was used to evaluate the difference in overall survival (OS) between the two groups using the log-rank test.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eEvaluation of predictive ability\u003c/h2\u003e \u003cp\u003eUnivariate Cox regression analysis and multivariate Cox regression analysis was performed to evaluate the resolution ability of METTL5. The predictive performance of METTL5 within 0.5, 1, and 1.5 years was assessed by receiver operating characteristic (ROC) curves using the survivalROC package.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eGene set variation analysis (GSVA)\u003c/h2\u003e \u003cp\u003eThe variation in biological processes between low- and high-METTL5 groups were performed by GSVA analysis using the R package 'GSVA'.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eDifferentially expressed genes (DEGs) analysis\u003c/h2\u003e \u003cp\u003eThe \u0026ldquo;limma\u0026rdquo; package of R software was used to identify the DEGs between high- and low- METTL5 expression groups. The cutoff criteria were set as | log2 fold change (FC) | \u0026gt; 0.5 and p\u0026thinsp;\u0026lt;\u0026thinsp;0.05. DEGs between normal and glioma tissues were selected based on the Wilcoxon rank test.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eCell culture and cell culture\u003c/h2\u003e \u003cp\u003eHuman LUSC cells lines (H1975 and A594 cells) were purchased from the Chinese Academy of Sciences Cell Bank and cultured in Dulbecco\u0026rsquo;s modified Eagle\u0026rsquo;s medium (DMEM) (Invitrogen) containing 10% FBS (HyClone) and 1% penicillin\u0026ndash;streptomycin (P/S).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eColony Formation Assay\u003c/h2\u003e \u003cp\u003eFor the colony formation assay, cells were seeded in 6-well plates at a density of 1 \u0026times; 10\u003csup\u003e3\u003c/sup\u003e cells per well and cultured for the 7\u0026ndash;10 days. The colonies were then stained with 0.2% crystal violet and documented.\u003c/p\u003e \u003cp\u003e \u003cb\u003eCCK-8 assay.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eCCK8 assay was used to assess tumor cells viability following the manufacturer\u0026rsquo;s instructions. GBM cells (2 \u0026times; 10\u003csup\u003e3\u003c/sup\u003e cells, 100 \u0026micro;L per well) were seeded into 96-well plates, and CCK-8 reagent was added at 24, 48, 72, and 96 hours. The absorbance at 450 nm was measured using a microplate reader.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eTranswell migratory experiment\u003c/h2\u003e \u003cp\u003eTo evaluate cell migratory ability, tumor cells (5 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e cells) were seeded into the upper chamber of Transwell inserts. The lower chamber was filled with 500 \u0026micro;L of complete medium containing 10% FBS to induce cell migration. After 24 hours of incubation, cells that migrated through the membrane were stained with 0.2% crystal violet and photographed by microscopy.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eWound healing assay\u003c/h2\u003e \u003cp\u003eCells were seeded in 6-well plate and incubated overnight. Next day, the inserts were removed, and serum-free medium was added. After 36 h. ImageJ was used to calculate the migratory rate.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eWestern blot\u003c/h2\u003e \u003cp\u003eRIPA buffer (Beyotime, Shanghai) was used to extract total protein from cells, then the protein concentration was detected by the BCA kit (Beyotime, China). Protein concentrations were determined using the BCA kit (Beyotime, China). Lysates were then separated by SDS-PAGE gels and transferred onto polyvinylidene difluoride (PVDF) membranes. Membranes were incubated overnight at 4\u0026deg;C with specific primary antibodies. After washing, membranes were incubated with HRP-conjugated secondary antibodies at room temperature for 2 hours.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eChemical Reagents, Antibodies, and Transfection\u003c/h2\u003e \u003cp\u003eAnti-METTL5 (proteintech, China, Cat# 16791-1-AP); CDC45 (proteintech, China, Cat# 15678-1-AP; METTL5 and CDC45 overexpression plasmids and short hairpin RNA (shRNA) METTL5 (\u003cb\u003eTable S4\u003c/b\u003e) were purchased from GeneChem (Shanghai, China). All transfections were performed according to the manufacturers\u0026rsquo; instructions (38589907).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eQuantitative RT\u0026ndash;PCR\u003c/h2\u003e \u003cp\u003eTotal RNA was extracted from cells using TRIzol reagent (Invitrogen, USA) according to the manufacturer\u0026rsquo;s instructions. 1 \u0026micro;g of RNA was applied for reverse transcription (Cat. #R323-01, Vazyme). Real-time PCR analysis was performed using SYBR Premix Ex TaqTM (Tli RNaseH Plus) (TaKaRa, Dalian, China). The amplification primers were listed in \u003cb\u003eTable S5\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003ePolysome profiling\u003c/h2\u003e \u003cp\u003eBriefly, cells were incubated with Cycloheximide (CHX; Sigma\u0026ndash;Aldrich) for 5 min at 37\u0026deg;C, and then the cells were washed with PBS containing 100 \u0026micro;g/mL CHX after removing the medium. Next, 400 \u0026micro;L of Triton X-100‐containing lysis buffer were added and incubated with the cells for 15 min. Each cell suspension was centrifuged, and the supernatant was collected. Subsequently, a 10%‐50% sucrose gradient was prepared in lysis buffer without Triton X‐100. Cell lysates were loaded onto a sucrose gradient and centrifuged at 30000 rpm for 4h at 4\u0026deg;C. The samples were then fractionated and analyzed with a Gradient Station.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eAnalysis of modified nucleosides by Liquid chromatography-Mass spectrometry (LC/MS)\u003c/h2\u003e \u003cp\u003eThe 18S rRNAs and mRNA were purified from cells by 10\u0026ndash;50% sucrose velocity centrifugation. Briefly, 1 \u0026times; 107 cells were seeded and detached in PBS at 0\u0026deg;C and resuspended in 500 \u0026micro;l Buffer. The cell suspension was centrifuged at 20 000 \u0026times; g for 20 min at 4\u0026deg;C, and extracts were thawed on ice and loaded on a 10\u0026ndash;50% sucrose density gradient and centrifuged at 23 000 \u0026times; g for 20 h in a Beckman L-90K centrifuge with a SW41Ti rotor. RNA was extracted from peak fractions with TRIreagent (Sigma #T9424). LC/MS was used to analyze the m6A levels of 18S rRNAs and mRNA[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eDual-luciferase reporter assays\u003c/h2\u003e \u003cp\u003eLuciferase reporter expression was measured using the Dual Luciferase Assay Kit (Promega, Madison, WI, USA). The results were normalized for transfection efficiency using Renilla luciferase activity.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003eStatistical analyses were performed using R, version 4.2.3. Survival analysis was performed by the Kaplan\u0026ndash;Meier method with a log rank test. Correlations were analyzed by using Pearson's correlation. Univariate and multivariable survival analysis were performed using Cox regression analysis. A two-tailed Student's t‐test was used to compare between groups for statistical significance. All experiments were performed for at least 3 times independently under similar conditions, unless otherwise specified in the figure captions. In all cases, p value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cb\u003eHigh-throughput library screening identifies METTL5 as a core m6A regulator in LUSC.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eBased on TCGA data, a total of 28 m6A regulators including 10 writers, 3 erasers and 15 readers were screened for subsequent studies. The process of m6A methylation was dynamically and reversibly regulated by these m6A regulators (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ea \u003cb\u003eand Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e\u003c/b\u003e). The investigation of CNV alteration frequency showed a prevalent CNV alteration in 28 regulators and most were focused on the amplification in copy number. YTHDF1, VIRMA, and METTL5 showed amplification frequencies, whereas ZC3H13 and RBM15 had CNV copy number deletions (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eb). In addition, the locations of CNV alterations in the 28 m6A regulators on the chromosomes are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ee. Compared to normal tissues, m6A regulators with amplificated CNV demonstrated remarkedly higher expression in LUSC tissues, and vice versa (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eb \u003cb\u003eand c\u003c/b\u003e). The comprehensive landscape of m6A regulator interactions, regulator connection and their prognostic significance for LUSC patients was depicted with the m6A regulator network \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ed\u003cb\u003e)\u003c/b\u003e. We found that not only exhibited significant correlations in expression within the same functional category but also among writers, erasers, and readers. Importantly, based on risk and survival analysis, the 3 best hints, METTL5, HNRNPC, and IGF2BP3, were screen, of which METTL5 overexpression exhibited the worst overall survival (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ef-h). Taken together, these data further shed light on the oncogenic role of METTL5 in tumour progression.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eMETTL5 is an independent prognostic factor in LUSC\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eBased on the TCGA dataset, high METTL5 expression was related with higher risk score and poorer OS status in LIHC patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea). Moreover, the receiver operating characteristics (ROC) curve analysis of the promising predictive value for METTL5 expression showed that the areas under the curves (AUCs) for 0.5-, 1-, and 1.5-year OS were 0.613, 0.611, and 0.620, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb). The multi-index ROC analysis revealed that the AUC of METTL5 was significantly better than those of other clinicopathological indicators (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb) (such as age, gender, and stage). In univariate Cox analysis, stage (p\u0026thinsp;\u0026lt;\u0026thinsp;0.009) and risk score (p\u0026thinsp;\u0026lt;\u0026thinsp;0.017) were significantly correlated with OS (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ec). In multivariate Cox analysis, only METTL5 (p\u0026thinsp;\u0026lt;\u0026thinsp;0.017) was an independent prognostic factor (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ed). Together, these data illustrate METTL5 is an independent prognostic factor in LUSC.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eMETTL5 promotes tumor progression in LUSC\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eTo explore the biological function of METTL5 in LUSC, we transfected NETTL5 knockdown or overexpression in H1975 and A549 cells. Transfection efficiency was evaluated by western blot and qPCR (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ea-d). Colony formation assays and CCK-8 showed that METTL5 regulated cell proliferation and colony formation ability (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ee-f). In addition, METTL5 also impacted cell migratory ability in H1975 and A549 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eg-h). Therefore, these results suggested that METTL5 promotes tumor progression in LUSC.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eFunctional annotations of METTL5 in LUSC\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eThe correlations between METTL5 expression and clinical properties were examined in the TCGA dataset. High METTL5 expression level was related with older age, gender, and tumor stage (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ea). Single-sample GSEA (ssGSEA) algorithm was used to evaluate the associations between METTL5 expression and immune cell infiltration, the results showed that high-METTL5 patients were slightly increased immune activity than the low-METTL5 patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eb). Additionally, Gene set variation analysis (GSVA) was performed to explore the underlying molecular mechanisms differing in the high-METTL5 and low-METTL5 subgroups of LIHC patients. The results showed that high- METTL5 patients were mainly related with mitotic spindle, G2M checkpoint, E2F targets (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ec\u003cb\u003e)\u003c/b\u003e, and cell cycle signaling pathway in the TCGA dataset (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ed).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eProtein\u0026ndash;protein interaction network and univariate cox regression analyses\u003c/h2\u003e \u003cp\u003eTo further investigate the potential biological behavior of METTL5 modification pattern, we determined the DEGs between high- METTL5 and low- METTL5 expression groups using limma package. The PPI network of the interactions among DEGs was performed using STRING database (confidence value\u0026thinsp;\u0026gt;\u0026thinsp;0.8) (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003ea), which were visualized in Cytoscape v3.8.2 (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eb). The top 30 genes were represented based on the number of nodes using bar plots, which may serve as hub nodes in the network (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003ec \u003cb\u003eand Table S2\u003c/b\u003e). In addition, univariate Cox regression analyses showed that 31 genes were of prognostic significance among the DEGs (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003ed \u003cb\u003eand Table S3\u003c/b\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eMETTL5 promoted cell division cycle protein 45 (CDC45) translation via 18S rRNA methyltransferase.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eBased on differentially expressed genes (DEGs) between high-METTL5 and low-METTL5 expression groups, CDC45 was identified through the intersection analysis of the top 10 prognostic significance and the top 10 hub genes in the PPI network (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003ea). Subsequently, the expression and potential role of CDC45 were further explored using the TCGA dataset. The expression of CDC45 was significantly increased in LUSC comparing normal tissue (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eb-c). K-M analysis showed that LUSC patients with CDC45 overexpression had poor survival (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003ed). Interestingly, METTL5 knockdown or overexpression regulated CDC45 protein expression but did not significantly alter the translation levels of CDC45 (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003ee-f). METTL5 regulates ribosome function by methylating 18S rRNA, resulting in changing indicated proteins levels[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Then, polysome fractionation analysis was used to determine whether METTL5 has an impact on CDC45 translation in METTL5-WT and METTL5‐KD cells, the results showed that METTL5 knockdown had no effect on the profile of GAPDH mRNA, whereas CDC45 mRNA was transferred from the heavier polysomal fractions to the lighter fractions (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eg-h), which revealed that METTL5 regulated CDC45 mRNA translation. Therefore, we investigated whether CDC45 translational activity is dependent on METTL5 methylase activity. Importantly, LC/MS showed that METTL5 knockdown reduced the m6A level of 18S rRNA but had no effect on the m6A level of mRNA after separation of rRNA and mRNA (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003ei-j), which suggested that the translation of CDC45 is directly dependent on METTL5 18S rRNA methyltransferase activities. In addition, METTL3‐METTL14 complex, as a well‐known mRNA m6A methyltransferase, has been demonstrated to mediates DNA m6A methylation (m6dA) in vitro[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Notably, we were unable to fund modification changes in the m6da region of genomic DNA following METTL5 knockdown (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003ek), which demonstrated that METTL5 is not involved in DNA methylation. Subsequently, the luciferase reporter assay determined that METTL5 had no effect on CDC45 promoter activity (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003ei). Taken together, these dates reveal that METTL5 was a pure RNA methylase and exhibited no regulatory effect on DNA methylation.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eMETTL5 promotes LUSC progression through CDC45 expression\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eDue to silencing METTL5 could reduce CDC45 expression, rescue experiments were carried out to verify the interaction between METTL5 and CDC45 in LUSC progression. As expected, CDC45 overexpression could partially counteract the antitumor effects of MEETL5 knockdown on cell viability (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003ea), colony formation (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eb) and migration (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003ec-d). In addition, overexpression of CDC45 also promoted cell proliferation, colony formation and migration in H1975 and A549 cells, confirming the oncogenic effects of CDC45 (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003ea-d). Collectively, METTL5 promotes LUSC progression through CDC45 expression.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eN6-methyladenosine (m6A) modification, as crucial regulators of LUSC progression, highlight the importance of understanding the crosstalk between these biological processes[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Accumulating evidence has indicated that METTL5 is highly expressed and promotes tumor progression[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], however, the role of METTL5 in LUSC is not explored.\u003c/p\u003e \u003cp\u003eIn this study, among 28 m6A regulators (writers:10, erasers:3 and readers:15), we firstly identified the key m6A regulator METTL5 in LUSC using TCGA dataset through CNV alteration frequency, differential analysis, correlation analysis, and survival analysis. Then, we demonstrated that METTL5 was an independent prognostic factor in LUSC based on ROC curve, univariate analysis, and multivariate analysis. METTL5 has been confirmed to be overexpressed in a variety of tumors and affects patient prognosis, such as hepatocellular carcinoma[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e], Intrahepatic cholangiocarcinoma (ICC)[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e], and breast cancer [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. We confirmed bioinformatically that the METTL5 expression was significantly higher in LUSC than in normal samples, and patients with high METTL5 expression had a worse prognosis. In vitro experiments, we demonstrated that METTL5 promotes tumor progression in LUSC via CCK-8, colony formation assay, transwell migration assay, and wound healing assay.\u003c/p\u003e \u003cp\u003eNext, we further explored the function of METTL5 in LUSC, the results showed older age, gender, and tumor stage were positive with METTL5 expression level. Surprisingly, high- METTL5 expression were no obvious immune activity compared to low-METTL5 patients. METTL5, as one of the 18S rRNA methyltransferases, is important in protein translation and polysome formation[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Interestingly, METTL5 is an rRNA m6A methyltransferase and is not responsible for the m6A modification of mRNA[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Importantly, METTL5 enhances protein translation in cancer, reduces apoptosis, and promotes cell cycle progression[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Similarly, our GSVA showed high-METTL5 patients were mainly related with G2M checkpoint, E2F targets, and cell cycle signaling pathway.\u003c/p\u003e \u003cp\u003eTo further investigate the modification pattern of METTL5, DEGs were screened between high-METTL5 and low-METTL5 expression groups, and then subjected to the PPI network analysis and univariate Cox regression analyses. Finally, screening CDC45 may be regulated by METTL5 based on the intersection analysis of the top 10 prognostic significance and hub genes in the PPI network. CDC45 is an irreplaceable factor to initiate DNA replication in eukaryotic cells. Dysfunction of CDC45 results in cell proliferation inhibition even cell death[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. We confirmed bioinformatically that CDC45 was significantly upregulated in LUSC comparing normal tissue, and CDC45 overexpression showed poor survival. Notably, our results demonstrated that translation of CDC45 is directly dependent on METTL5 18S rRNA methyltransferase activities. In vitro experiments, rescue experiments were carried out to verify METTL5 promotes LUSC progression through enhancing CDC45 translation. Above data suggested METTL5-CDC45 axis has an important role in LUSC progression and provides a novel potential prognostic biomarker for LUSC.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn summary, we demonstrated that the m6A writer METTL5 contributes to the tumorigenesis and poor prognosis of LUSC by enhancing CDC45 translation, providing a distinct mechanistic insight in m6A-dependent, which should be helpful for developing CDC45 signaling‐targeted inhibitors.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eClinical information and high-throughput sequencing-counts were retrieved from the TCGA data (https://www.cancer.gov/ccg/research/genome-sequencing/tcga) portal, which is a publicly available database.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe reviewers are grateful for their helpful comments on this article.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors contributed to the analysis of data in this study. Conception and design: JF; Acquisition, analysis, and interpretation of data: JF and YY; Writing, review, and/or revision of the manuscript: YY; Performing the laboratory experiments: JF and YY; Administrative, technical, or material support: JF; Study supervision: JF. All authors contributed to the article and approved the submitted version.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the Science and Technology Plan of Jiangxi Provincial Health Commission, China (SKJP220212042).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that there are no potential conflicts of interest.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eYang, X. et al. m(6) A-Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis. \u003cem\u003eAdv. Sci. (Weinh)\u003c/em\u003e. \u003cb\u003e10\u003c/b\u003e (20), e2206744 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSiegel, R. L., Miller, K. D., Fuchs, H. E. \u0026amp; Jemal, A. Cancer statistics, 2022. \u003cem\u003eCA Cancer J. Clin.\u003c/em\u003e \u003cb\u003e72\u003c/b\u003e (1), 7\u0026ndash;33 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLau, S. C. M., Pan, Y., Velcheti, V. \u0026amp; Wong, K. K. Squamous cell lung cancer: Current landscape and future therapeutic options. \u003cem\u003eCancer Cell.\u003c/em\u003e \u003cb\u003e40\u003c/b\u003e (11), 1279\u0026ndash;1293 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang, Y. et al. Epigenetic modification of m(6)A regulator proteins in cancer. \u003cem\u003eMol. Cancer\u003c/em\u003e. \u003cb\u003e22\u003c/b\u003e (1), 102 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDeng, L. J. et al. m6A modification: recent advances, anticancer targeted drug discovery and beyond. \u003cem\u003eMol. Cancer\u003c/em\u003e. \u003cb\u003e21\u003c/b\u003e (1), 52 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Tran, N. et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. \u003cem\u003eNucleic Acids Res.\u003c/em\u003e \u003cb\u003e47\u003c/b\u003e (15), 7719\u0026ndash;7733 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRong, B. et al. Ribosome 18S m(6)A Methyltransferase METTL5 Promotes Translation Initiation and Breast Cancer Cell Growth. \u003cem\u003eCell. Rep.\u003c/em\u003e \u003cb\u003e33\u003c/b\u003e (12), 108544 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXia, P. et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. \u003cem\u003eCancer Commun. (Lond)\u003c/em\u003e. \u003cb\u003e43\u003c/b\u003e (3), 338\u0026ndash;364 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFu, Y., Lv, Z., Kong, D., Fan, Y. \u0026amp; Dong, B. High abundance of CDC45 inhibits cell proliferation through elevation of HSPA6. \u003cem\u003eCell. Prolif.\u003c/em\u003e \u003cb\u003e55\u003c/b\u003e (7), e13257 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimon, A. C., Sannino, V., Costanzo, V. \u0026amp; Pellegrini, L. Structure of human Cdc45 and implications for CMG helicase function. \u003cem\u003eNat. Commun.\u003c/em\u003e \u003cb\u003e7\u003c/b\u003e, 11638 (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYu, W. et al. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma. \u003cem\u003eFront. Immunol.\u003c/em\u003e \u003cb\u003e12\u003c/b\u003e, 706936 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWoodcock, C. B. et al. Human MettL3-MettL14 complex is a sequence-specific DNA adenine methyltransferase active on single-strand and unpaired DNA in vitro. \u003cem\u003eCell. Discov\u003c/em\u003e. \u003cb\u003e5\u003c/b\u003e, 63 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, N. \u0026amp; Zhan, X. Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. \u003cem\u003eEPMA J.\u003c/em\u003e \u003cb\u003e11\u003c/b\u003e (3), 485\u0026ndash;504 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDai, Z. et al. METTL5-mediated 18S rRNA m(6)A modification promotes oncogenic mRNA translation and intrahepatic cholangiocarcinoma progression. \u003cem\u003eMol. Ther.\u003c/em\u003e \u003cb\u003e31\u003c/b\u003e (11), 3225\u0026ndash;3242 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLeismann, J. et al. The 18S ribosomal RNA m(6) A methyltransferase Mettl5 is required for normal walking behavior in Drosophila. \u003cem\u003eEMBO Rep.\u003c/em\u003e \u003cb\u003e21\u003c/b\u003e (7), e49443 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeng, H. et al. N(6)-methyladenosine (m(6)A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. \u003cem\u003eNat. Metab.\u003c/em\u003e \u003cb\u003e4\u003c/b\u003e (8), 1041\u0026ndash;1054 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYadav, A. et al. DNA replication protein Cdc45 directly interacts with PCNA via its PIP box in Leishmania donovani and the Cdc45 PIP box is essential for cell survival. \u003cem\u003ePLoS Pathog\u003c/em\u003e. \u003cb\u003e16\u003c/b\u003e (5), e1008190 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDang, H. Q. \u0026amp; Li, Z. The Cdc45.Mcm2-7.GINS protein complex in trypanosomes regulates DNA replication and interacts with two Orc1-like proteins in the origin recognition complex. \u003cem\u003eJ. Biol. Chem.\u003c/em\u003e \u003cb\u003e286\u003c/b\u003e (37), 32424\u0026ndash;32435 (2011).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"LUSC, METTL5, CDC45, m6A modification","lastPublishedDoi":"10.21203/rs.3.rs-4891277/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4891277/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAbnormal N6-methyladenosine (m6A) modifications were associated with the occurrence, development, and metastasis of Lung squamous cell carcinoma (LUSC). However, the functions and mechanisms of m6A regulators in LUSC remained largely unclear. Here, we identified that METTL5 was specifically overexpressed and associated with poor prognosis in LUSC. Importantly, METTL5 promoted LUSC cell progression in an m6A-dependent manner, METTL5 silencing significantly inhibited proliferation and migratory ability of tumor cells in vitro. Mechanistically, METTL5 increased the translation of cell division cycle protein 45 (CDC45) via 18S rRNA methyltransferase. Therefore, our findings indicated that m6A writer METTL5 contributed to tumorigenesis and poor prognosis, providing a potential prognostic biomarker and therapeutic target for LUSC.\u003c/p\u003e","manuscriptTitle":"The m6A writer METTL5 promotes LUSC progression by enhancing CDC45 translation.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-20 13:36:01","doi":"10.21203/rs.3.rs-4891277/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5325ae4d-339d-405f-a846-2fa5ce0be66f","owner":[],"postedDate":"September 20th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":37642522,"name":"Biological sciences/Cancer/Tumour biomarkers"},{"id":37642523,"name":"Biological sciences/Cancer/Lung cancer/Non small cell lung cancer"}],"tags":[],"updatedAt":"2024-09-23T08:39:24+00:00","versionOfRecord":[],"versionCreatedAt":"2024-09-20 13:36:01","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4891277","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4891277","identity":"rs-4891277","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}